The dynamic interplay of host and viral enzymes in type III CRISPR-mediated cyclic nucleotide signalling

  1. Januka S Athukoralage
  2. Shirley Graham
  3. Christophe Rouillon
  4. Sabine Grüschow
  5. Clarissa M Czekster
  6. Malcolm F White  Is a corresponding author
  1. University of St Andrews, United Kingdom
  2. Stiftung Caesar, Germany

Abstract

Cyclic nucleotide second messengers are increasingly implicated in prokaryotic anti-viral defence systems. Type III CRISPR systems synthesise cyclic oligoadenylate (cOA) upon detecting foreign RNA, activating ancillary nucleases that can be toxic to cells, necessitating mechanisms to remove cOA in systems that operate via immunity rather than abortive infection. Previously, we demonstrated that the Sulfolobus solfataricus type III-D CRISPR complex generates cyclic tetra-adenylate (cA4), activating the ribonuclease Csx1, and showed that subsequent RNA cleavage and dissociation acts as an 'off-switch' for the cyclase activity (Rouillon et al., 2018). Subsequently, we identified the cellular ring nuclease Crn1, which slowly degrades cA4 to reset the system, and demonstrated that viruses can subvert type III CRISPR immunity by means of a potent anti-CRISPR ring nuclease variant AcrIII-1. Here, we present a comprehensive analysis of the dynamic interplay between these enzymes, governing cyclic nucleotide levels and infection outcomes in virus-host conflict.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been (will be) provided for Figures 2, 3, 4 and 6.

Article and author information

Author details

  1. Januka S Athukoralage

    Biomedical Sciences Research Complex, School of Biology, University of St Andrews, St Andrews, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1666-0180
  2. Shirley Graham

    Biomedical Sciences Research Complex, School of Biology, University of St Andrews, St Andrews, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2608-3815
  3. Christophe Rouillon

    Neuroethology institute, Stiftung Caesar, Bonn, Germany
    Competing interests
    The authors declare that no competing interests exist.
  4. Sabine Grüschow

    Biomedical Sciences Research Complex, School of Biology, University of St Andrews, St Andrews, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Clarissa M Czekster

    School of Biology, University of St Andrews, St Andrews, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  6. Malcolm F White

    Biomedical Sciences Research Complex, School of Biology, University of St Andrews, St Andrews, United Kingdom
    For correspondence
    mfw2@st-and.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1543-9342

Funding

Biotechnology and Biological Sciences Research Council (BB/S000313/1)

  • Malcolm F White

Wellcome (210486/Z/18/Z)

  • Clarissa M Czekster

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2020, Athukoralage et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,665
    views
  • 295
    downloads
  • 45
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Januka S Athukoralage
  2. Shirley Graham
  3. Christophe Rouillon
  4. Sabine Grüschow
  5. Clarissa M Czekster
  6. Malcolm F White
(2020)
The dynamic interplay of host and viral enzymes in type III CRISPR-mediated cyclic nucleotide signalling
eLife 9:e55852.
https://doi.org/10.7554/eLife.55852

Share this article

https://doi.org/10.7554/eLife.55852

Further reading

    1. Biochemistry and Chemical Biology
    2. Neuroscience
    Lena Kallweit, Eric Daniel Hamlett ... Scott Horowitz
    Research Article

    As the world population ages, new molecular targets in aging and Alzheimer’s disease (AD) are needed to combat the expected influx of new AD cases. Until now, the role of RNA structure in aging and neurodegeneration has largely remained unexplored. In this study, we examined human hippocampal postmortem tissue for the formation of RNA G-quadruplexes (rG4s) in aging and AD. We found that rG4 immunostaining strongly increased in the hippocampus with both age and with AD severity. We further found that neurons with the accumulation of phospho-tau immunostaining contained rG4s, rG4 structure can drive tau aggregation, and rG4 staining density depended on APOE genotype in the human tissue examined. Combined with previous studies showing the dependence of rG4 structure on stress and the extreme power of rG4s at oligomerizing proteins, we propose a model of neurodegeneration in which chronic rG4 formation is linked to proteostasis collapse. These morphological findings suggest that further investigation of RNA structure in neurodegeneration is a critical avenue for future treatments and diagnoses.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Sasha L Evans, Bethany A Haynes ... Rivka L Isaacson
    Insight

    Nature has inspired the design of improved inhibitors for cancer-causing proteins.